|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients with acute decompensated cirrhosis were given albumin infusions at 10 hospitals in the United Kingdom.
|
31446184 |
2019 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
For these reasons, we favor albumin administration to patients with decompensated cirrhosis wait-listed for liver transplantation.
|
30346096 |
2019 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Because ACLF patients have greater hemodynamic derangements than patients with decompensated cirrhosis, we investigated whether PICD could develop with modest-volume paracentesis (MVP) and the role of albumin infusion.
|
31849085 |
2019 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These effects might be responsible for the beneficial effects of albumin therapy on outcomes of patients with decompensated cirrhosis.
|
30905652 |
2019 |
|
Decompensated cirrhosis of liver
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Serum albumin levels (per mg/dL; HR: 0.83, 95% CI: 0.77-0.89, P < 0.001) and MELD-Na (per point; HR: 1.15, 95% CI: 1.04-1.28, P = 0.006) in cACLD and MELD-Na (per point; HR: 1.12, 95% CI: 1.05-1.19, P < 0.0001) in DC patients were the only parameters independently associated with first and further hepatic decompensation, respectively.
|
30107095 |
2019 |
|
Decompensated cirrhosis of liver
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We identified 5 baseline factors (body mass index, encephalopathy, ascites, and serum levels of alanine aminotransferase and albumin) associated with a reduction of CPT score to class A in patients with hepatitis C virus-associated decompensated cirrhosis receiving DAA therapy.
|
29535028 |
2018 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis.
|
30070728 |
2018 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
|
29861076 |
2018 |
|
Decompensated cirrhosis of liver
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Compensated cirrhosis (odds ratio [OR] compared to decompensated cirrhosis, 2.41; 95% CI, 1.16-5.02), albumin ≥ 3.5 g/dL (OR, 3.15; 95% CI 1.46-6.80), or total bilirubin ≤ 1.2 mg/dL (OR 3.34; 95% CI, 1.59-7.00) were associated with SVR12.
|
29306043 |
2018 |
|
Decompensated cirrhosis of liver
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients with decompensated cirrhosis admitted to the hospital with a serum albumin of <30 g/L are eligible, subject to exclusion criteria.
|
30344180 |
2018 |
|
Decompensated cirrhosis of liver
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The critically ill patient with decompensated cirrhosis has a unique physiology and alterations in albumin that need to be understood to properly resuscitate them and minimize morbidity and mortality.
|
29132516 |
2017 |
|
Decompensated cirrhosis of liver
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, human albumin solution infusions may be used to reduce circulating PGE2 levels, attenuating immune suppression and reducing the risk of infection in patients with acutely decompensated cirrhosis or ESLD.
|
24728410 |
2014 |